JP2017507959A - 選択された抗コリン作動性両性イオンの使用 - Google Patents

選択された抗コリン作動性両性イオンの使用 Download PDF

Info

Publication number
JP2017507959A
JP2017507959A JP2016556253A JP2016556253A JP2017507959A JP 2017507959 A JP2017507959 A JP 2017507959A JP 2016556253 A JP2016556253 A JP 2016556253A JP 2016556253 A JP2016556253 A JP 2016556253A JP 2017507959 A JP2017507959 A JP 2017507959A
Authority
JP
Japan
Prior art keywords
compound
hydroxyacetoxy
cyclopentyl
carboxymethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016556253A
Other languages
English (en)
Japanese (ja)
Inventor
ニコラス エス． ボドール，
ニコラス エス． ボドール，
Original Assignee
ボドール ラボラトリーズ， インコーポレイテッド
ボドール ラボラトリーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボドール ラボラトリーズ， インコーポレイテッド, ボドール ラボラトリーズ， インコーポレイテッド filed Critical ボドール ラボラトリーズ， インコーポレイテッド
Publication of JP2017507959A publication Critical patent/JP2017507959A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016556253A 2014-03-13 2015-03-12 選択された抗コリン作動性両性イオンの使用 Withdrawn JP2017507959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461952342P 2014-03-13 2014-03-13
US61/952,342 2014-03-13
PCT/US2015/020137 WO2015138700A1 (en) 2014-03-13 2015-03-12 Use of selected anticholinergic zwitterions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020050858A Division JP6732356B2 (ja) 2014-03-13 2020-03-23 選択された抗コリン作動性両性イオンの使用

Publications (1)

Publication Number Publication Date
JP2017507959A true JP2017507959A (ja) 2017-03-23

Family

ID=54072392

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016556253A Withdrawn JP2017507959A (ja) 2014-03-13 2015-03-12 選択された抗コリン作動性両性イオンの使用
JP2018511381A Active JP6750900B2 (ja) 2014-03-13 2016-08-26 選択された抗コリン作用性双性イオンの使用
JP2020050858A Active JP6732356B2 (ja) 2014-03-13 2020-03-23 選択された抗コリン作動性両性イオンの使用
JP2020115416A Active JP6968457B2 (ja) 2014-03-13 2020-07-03 選択された抗コリン作動性両性イオンの使用
JP2020134413A Active JP6981694B2 (ja) 2014-03-13 2020-08-07 選択された抗コリン作用性双性イオンの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018511381A Active JP6750900B2 (ja) 2014-03-13 2016-08-26 選択された抗コリン作用性双性イオンの使用
JP2020050858A Active JP6732356B2 (ja) 2014-03-13 2020-03-23 選択された抗コリン作動性両性イオンの使用
JP2020115416A Active JP6968457B2 (ja) 2014-03-13 2020-07-03 選択された抗コリン作動性両性イオンの使用
JP2020134413A Active JP6981694B2 (ja) 2014-03-13 2020-08-07 選択された抗コリン作用性双性イオンの使用

Country Status (3)

Country Link
US (2) US10632067B2 (enExample)
JP (5) JP2017507959A (enExample)
WO (2) WO2015138700A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
WO2017015485A1 (en) 2015-07-21 2017-01-26 Bodor Laboratories, Inc. Formulation for soft anticholinergic analogs
JP2017507959A (ja) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ， インコーポレイテッド 選択された抗コリン作動性両性イオンの使用
EP3478365A4 (en) * 2016-07-01 2020-03-04 Bodor Laboratories, Inc. COMPOSITIONS AND METHODS FOR TREATING COPD
TWI719046B (zh) 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
JP2023530679A (ja) * 2020-06-11 2023-07-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク フェノテロール臭化水素酸塩、β２アドレナリン受容体アゴニスト、及びその誘導体を用いて近視を予防及び治療するための方法及び組成物
CN116133665A (zh) * 2020-06-11 2023-05-16 纽约市哥伦比亚大学理事会 用于用鞘氨醇-1-磷酸受体调节剂芬戈莫德及其衍生物预防和治疗近视的方法和组合物
KR20230051153A (ko) * 2020-06-11 2023-04-17 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 히스톤 데아세틸레이스(hdac) 저해제인 트라이코스타틴 a 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
WO2003026585A2 (en) 2001-09-26 2003-04-03 Lukacsko Alison B Compositions and methods for inhibiting eccrine perspiration in humans
ATE529400T1 (de) 2005-11-10 2011-11-15 Nicholas S Bodor Weiche anticholinerge zwitterionen
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
CN101616640B (zh) * 2006-12-26 2013-02-27 Qlt插入传输公司 用于抑制视觉缺陷的给药植入体
ES2969237T3 (es) 2007-10-18 2024-05-17 Rose U Llc Formulaciones tópicas de glicopirrolato y una toallita que contiene las mismas
ES2673098T3 (es) 2013-03-15 2018-06-19 Bodor Laboratories, Inc. Esteres anticolinérgicos suaves para el tratamiento de la hiperhidrosis
JP2017507959A (ja) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ， インコーポレイテッド 選択された抗コリン作動性両性イオンの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMAZIE,2008, VOL.63, NO.3, PP.200-209, JPN6018049103, ISSN: 0004158381 *

Also Published As

Publication number Publication date
JP2018529666A (ja) 2018-10-11
JP6968457B2 (ja) 2021-11-17
JP2020158545A (ja) 2020-10-01
US20180243209A1 (en) 2018-08-30
JP6750900B2 (ja) 2020-09-02
WO2017040307A1 (en) 2017-03-09
JP2020105218A (ja) 2020-07-09
US10632067B2 (en) 2020-04-28
JP6732356B2 (ja) 2020-07-29
US10335367B2 (en) 2019-07-02
JP6981694B2 (ja) 2021-12-17
US20150374621A1 (en) 2015-12-31
JP2020176154A (ja) 2020-10-29
WO2015138700A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
JP6732356B2 (ja) 選択された抗コリン作動性両性イオンの使用
EP3681500B2 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
CN101495117B (zh) 含酰胺化合物的水性液体制剂
JP7174175B2 (ja) 近視の治療、近視の予防および／または近視の進行抑制のための医薬
JP2022540253A (ja) Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
CN114306331B (zh) 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
CN115776894A (zh) T型钙通道调节剂的使用方法
JP2021501803A5 (enExample)
WO2023202705A1 (zh) 一种眼用制剂及其在治疗老花眼中的应用
EP3616723B1 (en) Use of nicotinic acid or prazosin for treating myopia
JP2008517937A (ja) 眼科用組成物及びその使用方法
Kubaisi et al. Ocular allergy: an updated review
TWI654976B (zh) 選定的抗膽素激導性兩性離子之用途
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤
JP2023043810A (ja) アレルギー性結膜炎治療剤
Mavangira Caffeine and Eyes: Balancing the Benefits and Risks
Guan et al. Potential Application of Bendazac L-Lysine for Controlling Myopia Progression, as Demonstrated in Two Experimental Guinea Pig Myopia Models
Bikbov et al. The results of the intrastromal corneal segments (Keraring) implantation for keratoconus
HK40081663A (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
CN112243375A (zh) 选择性syk抑制剂的使用方法及药物组合物
HK40034331A (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
HK40034331B (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
JP2014024871A (ja) 視機能障害の予防または治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200323

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200420

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200423